Datar Cancer Genetics products

Cancertrack^TM is a non-invasive blood based investigation that detects cancer derived biomarkers with ultra-high precision, specificity and reliability. Cancertrack^TM can be used to monitor the disease /recurrence or changes in the tumor characteristics, as often as necessary, without the cost, risk and consequences of radiation from scans, hospitalisation, anaesthesia or painful surgical biopsies.

Trublood is an advanced non-invasive blood test (which provides diagnostically relevant information about cancers via a safe, simple and quick blood draw). Trublood^® evaluates blood sample to detect ‘Circulating Tumor Cells’ (CTCs), which are cancer cells that escape from the tumor and enter the blood stream. Trublood^® enriches these CTCs from the blood sample and confirms their identity via a process called ‘Immunocytochemistry’ (ICC). A positive CTC finding is indicative of the presence of cancer whereas when CTCs are undetectable, the patient may not have a cancer.

Cancertrack is an advanced non-invasive blood test which provides real time intel on the status of a malignancy from a safe, simple and quick blood draw. Cancertrack profiles molecular features in circulating tumor DNA and circulating tumor RNA and also evaluates ‘Circulating Tumor Cells’ (CTCs).

Chemo-scale is an advanced non-invasive test which provides therapeutically relevant information and is based on a safe, simple, and quick blood draw. Chemo-scale^™ investigates in vitro chemo-resistance in Circulating Tumor Associated Cells (CTACs) isolated from the blood sample. CTACs include cancer cells that escape from the tumor and enter the bloodstream (circulating tumor cells, CTCs) as well as tumor-associated cells (TACs) which contribute to tumor survival and growth. Chemo-resistance in CTACs may be associated with a risk of treatment failure and disease progression.

Pinaka^™ is an advanced non-invasive blood test which provides therapeutically relevant information via a safe, simple and quick blood draw. Pinaka^™ evaluates blood sample to detect ‘Circulating Tumor Cells’ (CTCs), which are cancer cells that escape from the tumor and enter the blood stream. Pinaka^™ enriches these CTCs from the blood sample and confirms their identity via a process called ‘Immunocytochemistry’ (ICC). Pinaka also determines the status of the above biomarkers on CTCs either via ICC or by fluorescent in situ hybridization (FISH). Patients diagnosed with some types of cancers may be advised additional testing of tumor tissue sample to determine the status of biomarkers including ER, PR, HER2 (ERBB2), EGFR and PDL1. The positive status of these biomarkers forms the basis for selection of targeted anticancer agents which are known to be more effective against cancer.